Table 5. Meta-analysis of the subgroup including studies performed in any stage of NSCLC, with their characteristics.
|
Group of NSCLC: all stages (n=6) | |||||||
|---|---|---|---|---|---|---|---|
| Study | Method | Threshold | QS (%) | N Pts | Bcl-2+ (%) | HR | 95% CI |
| Anton et al (1997) | IHC-clone 124 | >10 | 49 | 427 | 47 | 0.87 | 0.70–1.07 |
| Kim et al (1998) | IHC-clone 124 | NM | 79 | 238 | 72 | 1.80 | 1.1–2.9 |
| O'Neill et al (1996) | IHC-clone 124 | >1 | 55 | 54 | 35 | 1.34 | 0.53–3.44 |
| Ohsaki et al (1996) | IHC-clone 124 | >20 | 50 | 96 | 17 | 0.46 | 0.22–0.98 |
| Rao et al (1996) | IHC-clone 124 | NM | 45 | 41 | 61 | 0.63 | 0.22–1.84 |
| Walker et al (1995) | IHC-clone 124 | >50 | 46 | 27 | 44 | 0.18 | 0.03–0.97 |
| Overall (fixed-effects model) | 883 | 50 | 0.91 | 0.76–1.10 | |||
| Overall (random-effects model) | 0.85 | 0.53–1.37 | |||||
| χ2 statistic for heterogeneity=15.34, 5 df, P=0.009 | |||||||
The meaning of the symbols is described in Table 3.